Introduction
Awakn was a biotechnology company focused on developing new treatments for addiction. It is now owned by Solvonis Therapeutics, which continues to develop its main research programmes.
Awakn, commonly known as Awakn Life Sciences, was a clinical-stage biotechnology company that researched treatments for addiction and mental health conditions. Its best-known work involved combining medicine with structured psychological therapy to help people with severe alcohol use disorder.
Awakn is no longer operating as an independent publicly traded company. Solvonis Therapeutics acquired all of its shares and research assets on 27 May 2025. Its main treatment programmes have continued under new names within the Solvonis pipeline.
What Was Awakn Life Sciences?
Awakn Life Sciences was a biotechnology business that worked on medication-assisted treatments for addiction. Its main area of interest was alcohol use disorder, especially severe cases where established treatment options may not provide lasting results.
The company researched whether carefully controlled medical treatments could be combined with psychological support to reduce harmful drinking and help patients maintain recovery.
Awakn was previously associated with the stock ticker AWKN. The Canadian Securities Exchange now marks the company as delisted, meaning its shares are no longer actively listed there as a standalone public company.
Is Awakn Still an Independent Company?
No. Awakn Life Sciences is no longer an independent company.
Solvonis Therapeutics completed its acquisition of Awakn on 27 May 2025. The deal covered all outstanding Awakn shares, restricted share units and deferred share units. Solvonis therefore gained full ownership of Awakn and its research portfolio.
The acquisition did not mean that all Awakn research ended. Instead, the most important projects were moved into the Solvonis development pipeline and given updated programme names.
By April 2026, Solvonis described the acquisition as a major part of its transformation into a company focused on addiction, psychiatry and other central nervous system disorders.
What Happened to the AWKN-001 Programme?
AWKN-001 was Awakn’s main clinical research programme. After the acquisition, the programme was renamed and is now generally presented by Solvonis as SVN-001.
SVN-001 is an investigational treatment for severe alcohol use disorder. It combines:
- Intravenous ketamine administered in a controlled medical setting
- A structured relapse-prevention programme
- Cognitive behavioural therapy techniques
- Continued psychological support
The aim is not simply to give a patient a medicine. The programme studies whether a medical treatment and organised therapy can work together to support longer-term changes in drinking behaviour.
Solvonis reported in April 2026 that SVN-001 was in a Phase 3 programme for severe alcohol use disorder. The company said advancing this trial remained one of its main strategic priorities.
What Is the SVN-001 Phase 3 Trial?
A Phase 3 trial is a large and important stage of medical research. It is normally designed to provide stronger evidence about whether a treatment works, how safe it is and how it compares with another treatment or control group.
The SVN-001 trial is being conducted through NHS organisations in the United Kingdom. Solvonis stated that the research involved eight NHS trusts and was being managed by the University of Exeter’s Clinical Trials Unit.
The trial began in the third quarter of 2024. When Solvonis completed the acquisition in May 2025, it expected the study to finish in late 2026 or early 2027. Clinical research timelines can change as recruitment, data collection and regulatory work continue.
SVN-001 remains an investigational programme. A clinical trial does not mean that a treatment has received general approval or that it is suitable for every patient.
What Did the Earlier Ketamine Study Find?
The development of the programme was supported by an earlier Phase 2 study involving 96 people with severe alcohol use disorder.
Participants were divided into groups receiving ketamine or saline, together with either psychological therapy or alcohol education. The study found that three ketamine infusions were generally well tolerated within the controlled trial.
At the six-month follow-up, the ketamine groups had a greater percentage of alcohol-free days than the placebo groups. However, the researchers also explained that it was a proof-of-concept study with wide confidence intervals, and it did not find a significant difference in the overall relapse rate.
These findings were encouraging enough to support further research, but they should not be interpreted as proof that ketamine is an approved cure for alcohol addiction.
What Is SVN-002?
Solvonis is also developing SVN-002, another programme connected with alcohol use disorder.
As of April 2026, the company described SVN-002 as a United States-focused programme in Phase 2 planning for moderate-to-severe alcohol use disorder. This means it is at an earlier development stage than SVN-001.
The two programmes have related goals, but they should not be treated as the same project:
- SVN-001 focuses on severe alcohol use disorder and is in Phase 3 development in the United Kingdom.
- SVN-002 is being prepared for Phase 2 development in the United States for moderate-to-severe alcohol use disorder.
Did Awakn Operate in the United Kingdom?
Awakn had business operations and legal entities connected with the United Kingdom.
One company, Awakn Life Sciences UK Ltd, was incorporated in July 2020. Companies House records show that this particular UK company was dissolved on 4 December 2024 following an earlier winding-up process.
This should not be confused with the later acquisition of the wider Awakn group. The UK subsidiary’s dissolution and Solvonis’s purchase of Awakn’s research assets were separate corporate events.
The most important scientific programmes did not disappear with the UK company’s dissolution. They later became part of Solvonis’s research and development strategy.
Can Patients Receive the Awakn Treatment?
The main treatment discussed under the former Awakn name is still being researched.
People should not assume that SVN-001 is a standard treatment that can be requested from any doctor or clinic. It combines intravenous ketamine with specialised psychological therapy and is being evaluated through formal clinical trials.
Ketamine can produce serious physical and psychological effects. It should never be used for addiction treatment without qualified medical supervision.
Anyone experiencing alcohol dependence or dangerous withdrawal symptoms should contact a licensed healthcare professional or an appropriate addiction service rather than trying an experimental treatment independently.
Is AWKN Still a Stock?
AWKN was the ticker used for Awakn Life Sciences. The Canadian Securities Exchange currently labels its Awakn listing as delisted.
Some old financial pages may still display historical AWKN prices, charts or company details. Those pages do not necessarily show the company’s present legal or trading status.
After the 2025 acquisition, the former Awakn assets became part of Solvonis Therapeutics. Investors researching the old AWKN ticker should therefore check current official exchange and company announcements rather than relying on outdated price pages.
Are There Other Companies Called Awakn?
Yes. The word Awakn is used by several unrelated businesses, which can make the search keyword confusing.
One business using the name describes itself as an AI-automation company. It promotes workflow automation, custom AI agents, business integrations and AI strategy services. This company is separate from Awakn Life Sciences and has no stated connection to the biotechnology research discussed above.
Another company, Awakn Digital, describes its product as a lead-resurrection system. It says it uses artificial intelligence, email and text messages to reconnect businesses with inactive sales leads. This is also a separate business.
Readers should therefore check the full company name:
- Awakn Life Sciences relates to addiction-treatment research.
- Awakn AI relates to business automation.
- Awakn Digital relates to sales leads and customer re-engagement.
Why Is Awakn Still Being Searched?
The Awakn name continues to attract searches because the company’s earlier scientific work remains active under Solvonis.
People may search for Awakn to learn about:
- Experimental treatments for alcohol use disorder
- Ketamine-assisted psychological therapy
- The former AWKN stock
- The acquisition by Solvonis Therapeutics
- The current SVN-001 Phase 3 programme
- Other unrelated companies using the Awakn name
The keyword therefore represents both a former biotechnology company and several newer brands.
Frequently Asked Questions
What does Awakn mean?
In biotechnology searches, Awakn usually refers to Awakn Life Sciences, a former independent company that researched treatments for addiction.
Who owns Awakn Life Sciences?
Solvonis Therapeutics acquired all of Awakn Life Sciences on 27 May 2025.
What happened to Awakn?
Awakn was acquired by Solvonis. Its main research assets were moved into the Solvonis development pipeline.
What is AWKN-001 called now?
Awakn’s former AWKN-001 programme is now generally called SVN-001 by Solvonis. It is being studied as a possible treatment for severe alcohol use disorder.
Is Awakn still listed on the stock market?
The Canadian Securities Exchange marks the former AWKN listing as delisted.
Does Awakn provide an approved alcohol-addiction cure?
No. The main programme remains investigational and is being studied through clinical trials. It should not be presented as an approved cure.
Is the Awakn AI company the same business?
No. The AI-automation company using the Awakn name is separate from Awakn Life Sciences.
Final Summary
Awakn Life Sciences was a biotechnology company best known for researching medication-assisted treatments for addiction, especially severe alcohol use disorder.
The company is no longer independent. Solvonis Therapeutics acquired Awakn in May 2025 and continued its leading research under updated programme names.
The most important former Awakn programme is now known as SVN-001. It combines intravenous ketamine with structured relapse-prevention therapy and remains in Phase 3 research in the United Kingdom.
Searchers should also remember that several unrelated AI, marketing and wellness businesses use similar Awakn or AWKN names. Checking the full name is the easiest way to identify the correct company.
